Clinical studies have shown that Veliparib, which has the lowest PARP-trapping activity, can effectively treat platinum-resistant or partially platinum-sensitive BRCA-mutated epithelial ovarian cancer, with a response rate comparable to that of other PARPi (226). Here, PARP1 is linked to ovarian carcinoma.